By abhat@reaganud… on
Email
info@athersys.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=athersys&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=c&recrs=d&recrs=f&recrs=k
Acknowledgement
One week
EA Page
https://www.athersys.com/multistem-therapy/compassionate-use-policy/default.aspx
COVID-19 Information

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

We are running a Pivotal Phase 2/3 clinical trial evaluating MultiStem cell therapy in COVID-19 induced ARDS patients. This trial is a multicenter study with an open-label, single active treatment arm for cohort 1 followed by a double-blind, randomized, placebo-controlled Phase 2/3 portion. The primary objectives of the MACOVIA study are to evaluate the safety and efficacy of MultiStem therapy as a treatment for subjects with moderate to severe ARDS due to COVID-19.

For more info: https://www.athersys.com/clinical-trials/ards/default.aspx

Stage
Phase 2
Phase 3
Company Type
Late Onset Intervention